Glatiramer effective in delaying clinical MS

June 2008
Formulary;Jun2008, Vol. 43 Issue 6, p220
Academic Journal
The article reports on the findings of the study called PRECISE, a randomized trial of patients presented with a single clinical episode and a magnetic resonance imaging (MRI) scan suggestive of multiple sclerosis (MS). This study found that glatiramer provides a new option for delaying conversion of clinically isolated syndrome (CIS) to clinically definite MS (CDMS). Details on the outcomes of the clinical trials involving glatiramer are presented.


Related Articles

  • The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders. Durelli, L.; Barbero, P.; Bergui, M.; Versino, E.; Bassano, M.; Verdun, E.; Ferrero, B.; Rivoiro, C.; Ferrero, C.; Picco, E.; Ripellino, P.; Viglietti, D.; Giuliani, G.; Montanari, E.; Clerico, M. // Journal of Neurology;Sep2008, Vol. 255 Issue 9, p1315 

    We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNβ-1b) 375 μg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNβ-1b 250 μg, i.e., with MRI activity or relapses. The...

  • Glatiramer, interferon beta-1b comparable in early RRMS.  // Formulary;Jun2008, Vol. 43 Issue 6, p222 

    The article reports on the findings of the study regarding the efficacy of interferon beta-1b with glatiramer for reducing relapse risk in patients with early relapsing-remitting multiple sclerosis (RRMS). Study author Paul O'Connor of St. Michael's Hospital in Toronto, Ontario found that the...

  • Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β in Relapsing-Remitting Multiple Sclerosis. Zhang, Xinke; Hay, Joel; Niu, Xiaoli // CNS Drugs;Jan2015, Vol. 29 Issue 1, p71 

    Objective: The aim of the study was to compare the cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate, and intramuscular (IM) interferon (IFN)-β as first-line therapies in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). Methods: A Markov model was...

  • Overview of London trial of intramuscular interferon-β1a in primary-progressive multiple sclerosis. Miller, David H.; Leary, Siobhan M.; Thompson, Alan J. // Multiple Sclerosis (13524585);Jun2004 Supplement, Vol. 10, p56 

    This short monograph describes the rationale, design and outcome of a pilot study of beta interferon in patients with primary progressive MS. A total of 50 patients were studied for 2 years using a randomized, double-blinded, placebo-controlled design. There was an emphasis on using MRI measures...

  • Neutralizing antibodies and interferon treatment of multiple sclerosis: addressing the open questions. Oger, J. // Multiple Sclerosis (13524585);May2007 Supplement 1, Vol. 13, pS5 

    The article discusses the significance of neutralizing antibodies (NAbs) and interferon on the treatment for multiple sclerosis (MS). The interferon beta therapies signified clear disease-modifying activity in MS that reduced relapse rate and magnetic resonance imaging disease burden. It is...

  • Determinants of Gd-enhanced MRI response to IFN-β-1a treatment in relapsing-remitting multiple sclerosis. Koudriavtseva, T.; Pozzilli, C.; Fiorelli, M.; Gasperini, C.; Bagnato, F.; Galgani, S.; Frontoni, M.; Ciccarelli, O.; Bastianello, S. // Multiple Sclerosis (13524585);Oct98, Vol. 4 Issue 5, p403 

    The decision to use interferon beta (IFN-β) as a treatment for relapsing-remitting multiple sclerosis (RRMS) is based on both clinical characteristics and course of the disease. To better identify the profile of responders, the relationships between baseline clinical/MRI characteristics and...

  • Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis. Comi, Giancarlo; Filippi, Massimo; Rocca, Maria A.; Jeffery, Douglas; Kappos, Ludwig; Montalban, Xavier; Boyko, Alexey // New England Journal of Medicine;3/15/2012, Vol. 366 Issue 11, p1000 

    Background: Two proof-of-concept clinical trials have provided evidence that laquinimod reduces disease activity in patients with relapsing�remitting multiple sclerosis. Methods: We conducted a randomized, double-blind, phase 3 study at 139 sites in 24 countries. A total of 1106 patients...

  • Induced Brain Plasticity after a Facilitation Programme for Autobiographical Memory in Multiple Sclerosis: A Preliminary Study. Ernst, Alexandra; Botzung, Anne; Gounot, Daniel; Sellal, François; Blanc, Frédéric; De Seze, Jerome; Manning, Liliann // Multiple Sclerosis International;2012, p1 

    This preliminary study tackles the assessment and treatment of autobiographical memory (AbM) in relapsing-remitting multiple sclerosis (RR-MS) patients. Our aim was to investigate cerebral activation changes, following clinical improvement of AbM due to a cognitive training based on mental...

  • Disease-modifying treatments for progressive multiple sclerosis. Comi, Giancarlo // Multiple Sclerosis Journal;Oct2013, Vol. 19 Issue 11, p1428 

    The last 20 years have seen major progress in the treatment of relapsing–remitting multiple sclerosis (RRMS) using a variety of drugs targeting immune dysfunction. In contrast, all clinical trials of such agents in primary progressive multiple sclerosis (PPMS) have failed and there is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics